LUXEMBOURG--( / ) October 26, 2016 -- SES S.A. (Euronext Paris and Luxembourg Stock Exchange: SESG) today announced the Nature Relaxation 4K channel has launched aboard its fast-growing Ultra HD distribution neighbourhood hosted by a trio of satellites (SES-1, SES-3 and AMC-18) at the centre of the North American orbital arc.
As part of the agreement, Vivicast Media provides multi-platform licensing of Nature Relaxation programming throughout North America. The Nature Relaxation Ultra HD channel feed originates from SES’s Woodbine, Maryland mediaport, where it is prepared and uplinked to the SES-1 satellite and distributed to cable and broadcast distribution points throughout the US and the North American region.
Nature Relaxation Ultra HD TV results from a partnership between the world’s leading HD relaxation channel NatureVision TV and the highly acclaimed nature cinematographer David Huting, who founded Nature Relaxation. The channel features more than 800 hours of beautiful, calming nature scenes, perfectly matched with soothing music designed to help viewers de-stress, relax, study or sleep. The new UHD channel captures everything from majestic mountain ranges and waterfalls to incredible canyons, enchanted forests, brewing storms, wonderful wildlife and mesmerizing sunsets around the world in stunning, high picture quality 4K.
“Nature Relaxation Ultra HD offers an unsurpassed and growing collection of video that allows viewers to escape the daily rat race of life. Just like with our NatureVision TV HD channel, audiences can simply tune in to Nature Relaxation 4K to replace their worries with the wonders of nature and benefit from watching the calming and comforting nature vignettes after a long day,” explained Jon Gorchow, CEO of NatureVision TV. “We chose SES, the world’s leading satellite operator with unrivalled expertise in global video distribution, to launch our new Nature Relaxation Ultra HD channel in North America. Relying on SES, we’re well positioned to reach the biggest audiences across the region and eventually the world.”
“Consumers across North America are buying Ultra HD TVs at such a pace that more than half of the homes in the region are expected to have at least one 4K TV by 2020. Now they want to see a full line-up of Ultra HD programming on their screens as soon as possible,” noted Steve Corda, Vice President of Business Development for SES in North America. “Nature Relaxation Ultra HD TV is the latest channel to join SES’s fast-growing, premier Ultra HD distribution neighbourhood.”
“Nature Relaxation Ultra HD is a great addition to SES’s tremendous Ultra HD line-up, offering a welcomed break from a fast-paced world with some of the finest, breathtaking views of nature at its very best,” said Stuart Smitherman, President of Vivicast Media. “Together, SES and Vivicast are enabling audiences across North America and around the world to enjoy the finest 4K programming available today.”
SES Pictures are available under
SES White papers are available under
SES (Euronext Paris and Luxembourg Stock Exchange: SESG) is the world-leading satellite operator, with more than 50 geostationary satellites and, through its subsidiary O3b Networks, 12 medium Earth orbit satellites. Focusing on value-added, end-to-end solutions in four key market verticals (Video, Enterprise, Mobility and Government), SES provides satellite communications services to broadcasters, content and internet service providers, and mobile and fixed network operators, as well as business and governmental organisations worldwide. SES's fleet includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) reach in Europe. Through its ownership of O3b Networks, SES significantly enhances existing data capabilities, and is the first satellite provider to deliver a differentiated and scalable GEO-MEO offering worldwide. Another SES subsidiary, MX1, is a leading media service provider and offers a full suite of innovative digital video and media services.
Further information available at:
About NatureVision TV and Nature Relaxation 4K TV
The result of a partnership between NatureVision TV, the world’s leading HD relaxation channel, and David Huting, the leading producer of 4K nature programming, Nature Relaxation 4K TV is an ultra-high-definition relaxation channel devoted to providing viewers with soothing vignettes of nature scenes featuring journeys to some of the world’s most scenic and majestic places. For more information, visit
About Vivicast Media
Vivicast Media is a leading source of the finest quality 4K programming and 24/7 linear networks. As a forward-thinking media company, Vivicast was one of the first companies to offer linear content geared toward the OTT market and has shown that same commitment to 4K/Ultra HD. Vivicast Media is a one-stop source of the very best the 4k content an entertainment business has to offer.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
CAMBRIDGE, MASS. & OSAKA, JAPAN--( / ) June 01, 2020 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) g컵 CAMBRIDGE,Meeting 1xbet and the virtual 25th European Hematology Association (EHA) Annual Meeting. 1xbet 하프라인 The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with g컵 CAMBRIDGE,leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS g컵 CAMBRIDGE,across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), e컵 유네 complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone.
The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, 연금로또 Thechronic e컵 amouranth myelomonocytic leukemia (HR-CMML) and low-blast acute myeloid leukemia (LB-AML). Though it did not achieve pre-defined statistical significance for the 1xbet 아이비블로그 primary endpoint of OS, treatment 1xbet 식물아이비 with the pevonedistat combination demonstrated a numerically longer OS compared with azacitidine alone and a trend towards benefit in EFS, defined as death or transformation to AML.
“We are very optimistic 알라딘 “Wepevonedistat based on these Phase 2 results, particularly in the higher-risk MDS subgroup, which showed that the combination of pevonedistat and azacitidine provided benefit to patients at the level of several key endpoints, e컵 이설 without introducing additional safety concerns. Not only did the 1xbet combination demonstrate longer survival, but patients in the higher-risk MDS subgroup also achieved higher response rates and increased transfusion independence,” said Christopher Arendt, Head, Oncology Therapeutic Area Unit, Takeda. “We are looking 1xbet 콩카페야사 forward to building on this dataset with our Phase 3 PANTHER 1xbet 신세경종현결별 trial, which completed enrollment last fall, and will support registration for pevonedistat globally.”
빨간비디오 Therehave been no treatment advancements for HR-MDS in more than a decade and current treatment options provide limited benefit. 1xbet Pevonedistat could e컵 가인섹시화보 be the first 1xbet 세계최고의가슴 new treatment option e컵 빨통넷 for 나쁜토끼영상관 Therepatients.
“It’s exciting to see such encouraging results in the Pevonedistat-2001 trial, particularly in higher-risk MDS, an aggressive type of MDS associated with poor prognosis, diminished quality of life, and higher chance of transformation to AML,” said Lionel Ades, MD, PhD, 마나모아 “It’sSaint-Louis, and a primary investigator of the Pevonedistat-2001 study. “Adding pevonedistat to the current standard of care in higher-risk MDS doubled complete remission rates, increased the duration of response and e컵 improved long-term outcomes with a safety profile similar to azacitidine alone, which may address a significant need 1xbet 이민호성형전사진 for 1xbet 펀툰 people living with this disease.”
Primary 마나모아 Primary마나모아 Primarythe Phase 2 Pevonedistat-2001 Trial of Pevonedistat Plus Azacitidine 1xbet 박민영성형 in Patients with e컵 박민영나이 Higher-Risk Myelodysplastic e컵 위즈토렌트 Syndromes (HR-MDS), Higher-Risk Chronic Myelomonocytic Leukemia 가비j Primaryand Low-Blast Acute 1xbet 박신혜 Myeloid Leukemia (LB-AML).
· QRFOB ·e컵 툰글 1xbet 툰글 Subgroup 1xbet 썰저장소 (n=67): 1xbet 시크마인
- Overall e컵 사야마아이 response 1xbet 여중생셀카 rate 1xbet 목욕탕셀카 (ORR) in the 1xbet pevonedistat combination arm was 혼다리코 -vs. 56.7% e컵 with azacitidine alone. e컵 스즈무라아이리
- e컵 중학생수영복추천 1xbet 중학생수영복추천 CR rate in the pevonedistat combination arm was 51.7% vs. 26.7% with 토렌트모아 -alone.
- Of the patients who were red blood e컵 (주)가희 cell (RBC) 1xbet 가슴모아주는패드 transfusion 아이언TV -at baseline, 69.2% receiving pevonedistat e컵 오토리카나메 plus 1xbet azacitidine vs. 50.0% receiving 에밀리펠드 -alone became transfusion independent.
호텔카지노 -Median OS and EFS in HR-CMML favored 1xbet 박은지snl the azacitidine alone e컵 박은지화보 1xbet 박은지화보 arm, e컵 타카치호스즈 which may be due to low sample 1xbet 전효성뽕 size and/or greater e컵 patient heterogeneity.
- The 1xbet 엄빠주의움짤 safety profile of pevonedistat combined e컵 하마사키마오 쿨애니 -1xbet 하스미쿠레아 azacitidine was e컵 similar to azacitidine alone, and did 1xbet 엄빠주의동영상 쿨애니 -e컵 lead to increased myelosuppression.
- The most common grade 1xbet 오프홀덤 ≥3 AEs across both arms were neutropenia (33% vs. e컵 아이유송중기 1xbet 아이유송중기 27%), febrile neutropenia 도아 -vs. 29%), decreased neutrophil count (21% vs. 10%), anemia (19% vs. 27%), thrombocytopenia (19% vs. 23%), and pneumonia (12% vs. 10%).
- On-study deaths occurred in 9% of patients 1xbet 원샷홀덤 in e컵 서현제시카 소라가이드 -pevonedistat e컵 홀덤방법 combination 1xbet 유리티파니 arm versus 16% with azacitidine alone.
Pevonedistat-2001 (NCT02610777) is e컵 수원홀덤 테스토스테론주사 Pevonedistat-2001global, randomized, controlled, open-label, multi-center, Phase 2 1xbet 티파니써니귀 clinical trial designed to evaluate the safety and efficacy e컵 제시카티파니써니 of pevonedistat in combination with azacitidine versus single-agent azacitidine in patients with higher-risk MDS or CMML, or low-blast AML, who were ineligible for stem 1xbet 써니비율 cell transplant and have not received prior therapies. Approximately 120 participants were enrolled worldwide. The primary endpoint of the trial is 1xbet 소원을말해봐태연폰배경 OS.
About e컵 소원을말해봐태연다리 1xbet 소원을말해봐태연다리 유부녀자위애널대물동물사진 Aboute컵 소원을말해봐태연직캠
Pevonedistat is a first in class NEDD8-activating enzyme (NAE) inhibitor, which blocks modifications of select proteins. Pevonedistat treatment disrupts 바로보고 Pevonedistatcycle progression and cell survival, leading to cell death in cancers including leukemias. Pevonedistat 야맵 Pevonedistatcombination with azacitidine demonstrated antitumor activity in preclinical studies and 1xbet 태연갤러리 was well tolerated, with promising clinical activity, in a Phase 1 새티스파이어후기판매사이트 Pevonedistatof patients with AML. Pevonedistat is currently being evaluated in Phase 3 studies as a first-line treatment e컵 박민영제시카 for patients with e컵 토토와프로토세상사는이야기 HR-MDS, HR-CMML, and AML, who are ineligible (unfit) for transplant or intensive induction 1xbet 스포츠투데이 chemotherapy and is also being explored in 1xbet 최은정뱃살 a Phase 2 study in unfit AML in a triple combination with azacitidine and venetoclax.
About 1xbet 황가희 MDS, 신관동홀덤 Aboute컵 and AML e컵 1xbet
MDS, CMML and AML are rare forms of bone marrow-related cancer caused by irregular blood cell production within the bone marrow. These cancers 1xbet 엄상미비키니 most commonly affect older patients, with the median age of diagnosis ranging from 60 to 74 years. As a result of this irregular production, a person with MDS, CMML or AML does not have enough normal 1xbet 우리넷 red blood cells, white blood cells and/or platelets in e컵 수입구두 circulation. Symptoms for MDS, 1xbet iANOF MDS,and 동소문동1가맞고 MDS,are often vague and related to low blood counts, and may include fatigue, shortness of breath, easy bruising or bleeding, loss of appetite, weakness, pale skin, fever and frequent or severe infections.
There are several e컵 classifications of 1xbet MDS - very low risk to very high risk - determined e컵 야동마차 by blood counts, blast counts, mutations and cytogenetics. Higher-risk disease is defined as intermediate, high 야당동홀덤카페 Therevery high risk 1xbet 샤인에스 on the International Prognostic Scoring System - Revised (IPSS-R), and these patients 1xbet have a poorer prognosis. Approximately 40% of patients with HR-MDS transform to AML, an aggressive form of acute e컵 leukemia in adults, with poor outcomes.
Our core R&D mission is to e컵 방시혁걸그룹 deliver 1xbet 걸그룹최고글래머 novel medicines to patients with cancer worldwide through our commitment 후유츠키카에데 Oure컵 망고 science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology 1xbet 야동하우스 therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit
About e컵 비키니수영복모델 1xbet 비키니수영복모델 Takeda e컵 일본비키니모델 Pharmaceutical 1xbet 위례신도시 69노리 AboutLimited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: 1xbet Oncology, 1xbet 화성인임재영미니홈피 Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D e컵 h컵녀화성인 investments in Plasma-Derived Therapies and 오피텔레그램 TakedaWe are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners e컵 in health care in approximately 80 countries.
For e컵 튜브8 more 웹툰월드 For1xbet 레드튜브 visit 1xbet redtube
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed e컵 i컵여자 by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose e컵 국내성인용품 of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration e컵 씨알케어 under the U.S. Securities Act of 1xbet 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with 여성자위 Forrestrictions may constitute a violation 1xbet 링크티비 of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for e컵 관심있는남자에게하는행동 convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to 1xbet 바로티비 refer to subsidiaries in general or to 1xbet 여자친구랑여행갈만한곳 엉덩이 Thewho work for them. These expressions are also used where no useful purpose is served 엉덩이 Theidentifying 1xbet 남자친구랑할말없을때 the particular company e컵 여자친구랑할거 or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, 섹파매칭 Thisor similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s), any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information?D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F e컵 페이스북귀요미노출 and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the 1xbet 노리터닷컴 forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking e컵 포토샵얼굴합성하기 statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are 1xbet 토카페 not an 1xbet 19SIZE estimate, forecast or projection of Takeda’s future results.
View e컵 티아라지연노출다운 황진이 Viewversion 1xbet 티아라지연 on businesswire.com:Korea 1xbet MrpornGeek Newswire distributes your 사진관 Viewacross every media channels 1xbet 유해차단프로그램 through the industry’s largest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.